Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis.
From: www.nytimes.com
Biotech Psoriasis Drugs Hit a Cost Ceiling
Posted by Ruslan Abuzant at 8:24 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment